Because hydrophobic drugs are poorly soluble in water, administering them orally can be extremely difficult. When creating formulations, self-emulsifying drug delivery systems (SEDDS) can be utilized to enhance the oral absorption of highly lipophilic drug compounds. Being one of the top service providers for biological research and drug discovery, Creative Biolabs has created a number of cutting-edge and versatile lipid-based drug delivery (LDD) platforms that enable us to offer our global clientele quick and easy services. Our qualified staff is ready to assist you in reaching a significant advancement in the development of your medication delivery system.
For more information: self emulsifying drug delivery system

Bifidobacterium longum (B. longum) is one of several species of Bifidobacteria found in the human digestive flora. These bacteria can help the body defend against harmful bacteria that may target intestinal or intestinal pathogens.

Creative Biolabs has extensive experience to offer the antibody humanization service for therapeutic and diagnostic development. We have successfully performed 15 mouse/rat humanization projects during the past decade with at least one humanized antibody entered the clinical trials. We also provide humanization service to antibodies derived from other species, such as non-human primate (NHP), rabbit, dog, chicken, llama and etc. For more information: antibody humanisation

Due to the huge potential of ASGPR in the application of hepatopathies, Creative Biolabs has put effort into the research of ASGPR and gained remarkable achievements. It is a pleasure to share our experience with our partners all over the world and fight against liver diseases together.

In a new study, researchers have found that an unknown family of viruses has become endemic in wild African primates and causes fatal Ebola-like symptoms in some monkeys, and is poised to infect humans. The findings were published online Sept. 30, 2022, in the journal Cell, in a paper titled "Primate hemorrhagic fever-causing arteriviruses are poised for spillover to humans".

Despite the fact that this virus family, known as arterivirus, has been identified as a major hazard to macaques, no human infections have been documented to yet. It is unknown what effect this virus might have on humans if it jumped species. However, by comparing them to simian immunodeficiency virus (SIV), a precursor virus to human immunodeficiency virus (HIV) that originated in African monkeys, these authors urge caution that by observing arteritis viruses in animals and humans today, the global health community may be able to avoid another pandemic.

Sara Sawyer, professor of molecular, cellular, and developmental biology at the University of Colorado at Boulder and co-corresponding author of the paper, stated, "Animal viruses have been known to enter human cells, multiply, and evade some important immune mechanisms that we would think would protect us from animal viruses. This is really unusual. We should be concerned about them."

There are thousands of different viruses circulating in animals all over the world, the vast majority of which do not cause any symptoms. In recent decades, a growing number of viruses have made their way to humans, wreaking havoc on immune systems that have never had to deal with them. Middle East Respiratory Syndrome Coronavirus (MERS-CoV) in 2012, Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) in 2003, and SARS-CoV-2 (the coronavirus that causes COVID-19) in 2020 are among them.

For 15 years, Sawyer's lab has used laboratory techniques and tissue samples from wildlife around the globe to explore which animal viruses might be susceptible to infecting humans. She and the paper's lead author, Cody Warren, focused on arteritis viruses, which are abundant in pigs and horses but have received less attention in non-human primates (NHPs). They focused on simian hemorrhagic fever virus (SHFV), an ape arteritis virus that produces a lethal illness comparable to Ebola virus disease and was responsible for a devastating epidemic in captive macaque populations in the 1960s.

This new study indicates that a receptor protein known as CD163 is important in SHFV biology, helping it to penetrate and infect target cells. These researchers discovered, via a series of laboratory studies, that the virus is also quite proficient at attaching to the human form of CD163, entering human cells, and rapidly reproducing itself.

Simian arteritis virus, like HIV and its progenitor virus SIV, appears to assault immune cells, crippling important defensive mechanisms and replicating them in the body. "There are remarkable parallels between this virus and SIV, which created the HIV pandemic," Warren explained.

These authors underlined that another epidemic is not imminent and that the public should not be alarmed. They do, however, suggested that the global health community prioritize more studies on ape arteritis viruses, develop blood antibody testing against them, and investigate surveillance of human populations in close contact with animal carriers.
 

Primary human astrocytes are isolated from the human brain and can be used to study the function of the central nervous system and how nerve cells interact. Astrocytes are glial cells found in the brain and spinal cord.

Taking advantage of the CellRapeutics™ platform, Creative Biolabs provides customized, standardized, reliable and high-quality CAR-T preclinical in vivo assay services for clients across the world. Our one-stop service covers all aspects from cell biology to animal tests with a special emphasis on the construction of tumor xenograft models. For more information: car t in vivo assay

Monoclonal antibody-based immunotherapies against cancer and other infectious diseases are highly advantageous comparing to conventional therapeutic approaches due to their high specificity and affinity towards well-defined targets. Antibody-drug conjugates (ADCs) inherit such superiorities and more remarkably, expand the therapeutic window of the conjugated drugs (payloads), which are usually highly toxic and diverse in their biochemical nature. For more information: adc customer service

January 6, 2022—Researchers at the Perelman School of Medicine at the University of Pennsylvania published a research paper in Science titled: CAR-T cells produced in vivo to treat cardiac injury.

Heart damage or inflammation can induce fibroblasts to overproduce fibrous material, causing cardiac fibrosis, which hardens the heart muscle and impairs heart function. Heart failure, liver disease, and kidney failure are just a few of the major conditions that can result from cardiac fibrosis.

The FDA approved CAR-T cell therapy, also known as chimeric antigen receptor T-cell therapy, as the first CAR-T cell therapy to be marketed for the treatment of leukemia in 2017, ushering in a new age of CAR-T cell therapy.

To date, CAR-T cell therapies have necessitated the collection of a patient's own T cells, which are then genetically reprogrammed in the laboratory to recognize specific cancer cells, allowing them to identify and destroy cancer cells once they are reintroduced into the body. The entire procedure is complicated and time-consuming, resulting in a high price tag of hundreds of thousands of dollars.

The CAR-T cell therapies now on the market are all intended to treat blood malignancies, but they have shown promise in a variety of other disorders as well. Jonathan Epstein's team at the University of Pennsylvania's Perelman School of Medicine demonstrated in 2019 that CAR-T cell therapies can target overactive cardiac fibroblasts and restore heart function.

In a mouse model of heart failure, the scientists devised a transiently designed CAR-T cell therapy that reprograms T cells to detect cardiac fibrotic cells by injecting mRNA supplied by lipid nanoparticles (LNPs), which lowers fibrosis and restores cardiac function. The technology is comparable to an mRNA vaccine in that it only takes one injection to manufacture CAR-T cell therapies in vivo, and it is predicted to tackle the present issues of CAR-T treatments' complex procedure, long cycle time, and expensive price.

The paper's authors include Jonathan Epstein, chief scientist at the Perelman School of Medicine at the University of Pennsylvania, Drew Weissman, one of the founders of mRNA technology, as well as Carl June, the father of CAR-T.

The researchers created a new CAR-T cell therapy based on mRNA technology that targets fibroblast-activating protein (FAP) via mRNA recoding of the T cell receptor for distribution utilizing lipid nanoparticles (LNPs), a vector that has been widely utilized and proven in the COVID-19 mRNA vaccine. And because this LNP vector recognizes CD5, which is abundantly expressed by T cells, it can target T cells precisely and generate FAP-CAR-T cells.

The team then performed therapeutic experiments in a mouse model of heart injury, where mRNA was encapsulated by CD5/LNP and then injected into the mice. These mRNA molecules successfully entered the mouse T cells, effectively reprogramming the T cells and targeting them to attack activated fibroblasts. Because the mRNA was not integrated into the T cell genome, the reprogramming was only transitory, and the T cells recovered after a few days and no longer targeted fibroblasts. Importantly, mRNA-induced reprogramming of a high number of CAR-T cells led to a considerable decrease in cardiac fibrosis and restoration of normal heart size and function in mice in just a few days.

Because mRNA is only stable in the body for a short time (about a week), this in vivo-generated engineered CAR-T cell therapy is transient and does not act as long as traditional viral vector-based in vitro reprogrammed CAR-T cell therapies, and thus does not suppress fibroblasts for long periods of time or impair functions like wound healing.

The researchers said they'll keep testing this transitory mRNA-based CAR-T cell therapy and expect to move forward to human clinical trials as soon as possible.

Omicron, as the most transmissible variant of SARS-CoV-2, is rapidly spreading over the world and has displaced Delta as the dominant strain in a number of regions. Some experts have indicated that mucosal immunization of the respiratory system with an inhaled form of the vaccine may be more efficient in dealing with the Omicron strain in light of recent results that demonstrate Omicron infections are more concentrated in the upper respiratory tract. Several inhalation vaccines for COVID-19 are also on the horizon in the global fight against Omicron, and are expected to become another major weapon.

Omicron possesses more mutant sites and is more contagious than prior strains, with the majority of them residing in the upper respiratory system rather than the lungs.

While the existing intramuscular vaccines on the market today generally have only humoral and cellular immunity, the vaccine given in the arm produces antibodies in the blood, but few antibodies reach our nasopharyngeal mucosa, which, together with the gradual decline in the level of neutralizing antibodies in the body after vaccination, means a weakening of the immune effect, together with the new characteristics (high immune escape, infestation of the upper respiratory tract) arising from the mutation of strains such as Omicron. Therefore, a vaccine booster has become a widely promoted policy after mass vaccination.

Vaccines with mucosal immunological effects are more effective in preventing respiratory viral infections in general, but the inhaled COVID-19 vaccine accesses the respiratory system and lungs through inhalation, triggering triple protection against mucosal, humoral, and cellular immunity. As a result, while dealing with the Omicron strain, the inhalation vaccine becomes a potentially more effective approach.

Multiple studies back this up: Yale immunologist Akiko Iwasaki and her colleagues published a preprinted paper in which they found that a transnasal vaccine booster shot increased the production of strong antibodies and immune memory cells in the respiratory mucosa and improved protection against the initial vaccination in rats. Furthermore, studies published in the internationally renowned medical journal The Lancet found that adverse responses were less common following heterologous boosting with inhaled COVID-19 vaccine than after homologous boosting with the live attenuated vaccine.

The immunogenicity results showed that the peak was attained 28 days after the inhalation booster, and the neutralizing antibody level was significantly higher than that of the live attenuated vaccine homologous booster group, which was 10.7 times higher. There were no serious side effects in the inhalation group 28 days after booster vaccination, and there were no clinically significant lung function abnormalities in the different dose inhalation groups. It is safer, has fewer negative side effects, and is more suited to the elderly and children.

Inhalation vaccine development is also in full swing around the world, with Bharat India and Washington University in St. Louis collaborating on the BBV 154 vaccine, which entered clinical phase III earlier this year and is expected to be one of the world's fastest inhalation COVID-19 vaccines to hit the market.